Ferric Carboxymaltose Methemoglobinemia Study
A legfontosabb adatok
- Ki végzi
- Ordu University
- Hol
- Törökország23 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 977 fő vett részt
- Kezdés
- 2025. ápr. 14.
- Befejezés
- 2025. szept. 30.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Ferric Carboxymaltose (FCM)
- A regiszteradat frissítve
- 2025. november 19.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- FCM Group:
- Adults (≥18 years)
- Presence of anemia (Hb <12 g/dl in women, <13 g/dl in men)
- Low ferritin (<30 mcg/l)
- Patients for whom FCM administration has been decided in routine medical care practice; Control Group:; Healthy adult (≥18 years) individuals who applied to the internal medicine outpatient clinic, who had no current or pre-existing chronic disease, who did not have anemia and iron deficiency (ferritin ≥30 mcg/L)
Ki nem vehet részt
- Use of drugs associated with methemoglobinemia (acetylsalicylic acid, dapsone, chloroquine, metoclopramide, benzocaine, lidocaine, prilocaine, rasburicase, primaquine, sulfonamide, nitric oxide)
- Known methemoglobinemia-related diseases (Hb M disease, cytochrome b5 reductase deficiency, etc.)
- Presence of advanced organ failure (Stage 4 and 5 chronic kidney disease, Child C cirrhosis, NYHA class 3 and 4 chronic heart failure, respiratory failure requiring oxygen supplementation and similar processes)
- Presence of malignancy (with or without cure)
- Presence of active infection (CRP > 5 mg/dL) and/or other acute disorder/disease
- Those with B12 and/or folate deficiency
- Those with Charlson Comorbidity Index ≥3
- Pregnancy status
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Anemia that develops due to iron deficiency is called iron deficiency anemia. This common condition is treated with iron supplements taken either orally or given through an intravenous (IV) infusion. Ferric carboxymaltose (FCM) is one of the widely used, comparably newer IV iron preparations. Recently, several publications have raised the possibility that FCM may be associated with mild elevations in methemoglobin (metHb), a form of hemoglobin that cannot effectively deliver oxygen to tissues.
A teljes eredeti leírásKevesebb
Methemoglobinemia is a known, though uncommon, side effect of some drugs. While usually mild and self-limiting, in certain cases it can become clinically significant or even life-threatening. This observational study is being conducted across multiple centers to better understand how often methemoglobinemia occurs after administration of FCM. As part of routine care, venous blood samples will be used to measure metHb levels in patients receiving FCM, and these results will be compared with those from individuals not exposed to the drug.
A vizsgálat 2 csoportja
- FCM Group
It will represent the group of patients who will be administered ferric carboxymaltose (FCM), i.e., the exposed group.
Kezelés: Ferric Carboxymaltose (FCM)
- Control Group
It will represent the control group of patients who do not receive FCM or any form of iron therapy, i.e., the unexposed group.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Estimation of the Incidence of Methemoglobinemia Associated With Ferric Carboxymaltose Administration
- A regiszteradat frissítve
- 2025. november 19.